LENSAR (LNSR) 10-Q 8 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Jul. 31, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Registrant Name	LENSAR, INC.
Entity Central Index Key	0001320350
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		11,020,965
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	LNSR
Security Exchange Name	NASDAQ
Entity File Number	001-39473
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0125724
Entity Address, Address Line One	2800 Discovery Drive
Entity Address, City or Town	Orlando
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32826
City Area Code	888
Local Phone Number	536-7271
Document Quarterly Report	true
Document Transition Report	false

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue
Product and service revenue	$ 6,623	$ 6,782	$ 14,564	$ 12,714
Lease	1,415	1,140	2,814	2,251
Total revenue	8,038	7,922	17,378	14,965
Cost of revenue (exclusive of amortization)
Total cost of revenue	3,146	3,464	7,794	6,613
Operating expenses
Selling, general and administrative expenses	7,569	5,518	13,847	11,553
Research and development expenses	3,834	3,006	8,622	5,752
Amortization of intangible assets	287	309	596	622
Operating loss	(6,798)	(4,375)	(13,481)	(9,575)
Other income
Other income, net	39	13	48	31
Net loss	$ (6,759)	$ (4,362)	$ (13,433)	$ (9,544)
Net loss per share:
Basic	$ (0.67)	$ (0.47)	$ (1.34)	$ (1.03)
Diluted	$ (0.67)	$ (0.47)	$ (1.34)	$ (1.03)
Weighted-average number of shares used in calculation of net loss per share:
Basic	10,073	9,296	10,020	9,242
Diluted	10,073	9,296	10,020	9,242
Product
Revenue
Product and service revenue	$ 5,733	$ 6,056	$ 12,702	$ 11,214
Cost of revenue (exclusive of amortization)
Total cost of revenue	1,765	2,366	4,459	4,456
Service
Revenue
Product and service revenue	890	726	1,862	1,500
Cost of revenue (exclusive of amortization)
Total cost of revenue	897	830	2,377	1,638
Lease
Cost of revenue (exclusive of amortization)
Total cost of revenue	$ 484	$ 268	$ 958	$ 519

CONDENSED BALANCE SHEETS (Unaud

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 25,196	$ 31,637
Accounts receivable, net of allowance of $25 and $47, respectively	2,760	4,638
Notes receivable, net of allowance of $181 and $61, respectively	164	350
Inventories	5,856	6,488
Prepaid and other current assets	1,230	1,700
Total current assets	35,206	44,813
Property and equipment, net	680	756
Equipment under lease, net	7,161	6,690
Notes and other receivables, long-term, net of allowance of $1 and $2, respectively	29	121
Intangible assets, net	12,674	10,870
Other assets	2,950	3,215
Total assets	58,700	66,465
Current liabilities:
Accounts payable	4,191	2,694
Accrued liabilities	4,372	4,604
Contingent consideration	1,200
Deferred revenue	937	904
Operating lease liabilities	521	512
Total current liabilities	11,221	8,714
Long-term operating lease liabilities	2,540	2,803
Other long-term liabilities	37	69
Total liabilities	13,798	11,586
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, par value $0.01 per share, 10,000 shares authorized at June 30, 2022 and December 31, 2021; no shares issued and outstanding at June 30, 2022 and December 31, 2021
Common stock, par value $0.01 per share, 150,000 shares authorized at June 30, 2022 and December 31, 2021; 11,021 and 10,990 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	110	110
Additional paid-in capital	135,819	132,363
Accumulated deficit	(91,027)	(77,594)
Total stockholders’ equity	44,902	54,879
Total liabilities and stockholders’ equity	$ 58,700	$ 66,465

CONDENSED BALANCE SHEETS (Una_2

CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 25	$ 47
Notes receivable, allowance	181	61
Notes and other receivables, long-term, allowance	$ 1	$ 2
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	11,021,000	10,990,000
Common stock, shares outstanding	11,021,000	10,990,000

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (13,433)	$ (9,544)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,110	670
Amortization of intangible assets	596	622
Non-cash operating lease cost	260	258
Provision for expected credit losses	125	5
Write-down of inventory		4
Loss on disposal of property and equipment		120
Stock-based compensation expense	3,244	3,750
Changes in operating assets and liabilities:
Accounts receivable	1,871	(691)
Prepaid and other current assets	470	423
Inventories	(818)	(840)
Accounts payable	1,497	326
Accrued liabilities	(232)	(1,236)
Other	(87)	52
Net cash used in operating activities	(5,397)	(6,081)
Cash flows from investing activities
Purchase of property and equipment	(56)	(134)
Net cash used in investing activities	(56)	(134)
Cash flows from financing activities
Payment of contingent consideration	(1,200)
Proceeds from issuance of common stock under employee stock purchase plan	212	170
Net cash (used in) provided by financing activities	(988)	170
Net decrease in cash and cash equivalents	(6,441)	(6,045)
Cash and cash equivalents at beginning of the period	31,637	40,599
Cash and cash equivalents at end of the period	25,196	34,554
Supplemental cash flow information
Cash paid for taxes	10	19
Supplemental schedule of non-cash investing and financing activities
Transfer from Inventories to Equipment under lease, net	1,416	1,860
Transfer from Inventories to Property and equipment, net	$ 34
Accounts payable for purchases of Property and equipment		$ 51

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2020	$ 67,210	$ 109	$ 125,094	$ (57,993)
Beginning Balance, Shares at Dec. 31, 2020		10,933
Stock-based compensation	2,301		2,301
Net loss	(5,182)			(5,182)
Ending Balance at Mar. 31, 2021	64,329	$ 109	127,395	(63,175)
Ending Balance, Shares at Mar. 31, 2021		10,933
Beginning Balance at Dec. 31, 2020	67,210	$ 109	125,094	(57,993)
Beginning Balance, Shares at Dec. 31, 2020		10,933
Net loss	(9,544)
Ending Balance at Jun. 30, 2021	61,628	$ 110	129,055	(67,537)
Ending Balance, Shares at Jun. 30, 2021		10,957
Beginning Balance at Mar. 31, 2021	64,329	$ 109	127,395	(63,175)
Beginning Balance, Shares at Mar. 31, 2021		10,933
Issuance of common stock under the 2020 ESPP	170	$ 1	169
Issuance of common stock under the 2020 ESPP, Shares		24
Stock-based compensation	1,491		1,491
Net loss	(4,362)			(4,362)
Ending Balance at Jun. 30, 2021	61,628	$ 110	129,055	(67,537)
Ending Balance, Shares at Jun. 30, 2021		10,957
Beginning Balance at Dec. 31, 2021	54,879	$ 110	132,363	(77,594)
Beginning Balance, Shares at Dec. 31, 2021		10,990
Restricted stock awards cancelled		(5)
Stock-based compensation	1,607		1,607
Net loss	(6,674)			(6,674)
Ending Balance at Mar. 31, 2022	49,812	$ 110	133,970	(84,268)
Ending Balance, Shares at Mar. 31, 2022		10,985
Beginning Balance at Dec. 31, 2021	54,879	$ 110	132,363	(77,594)
Beginning Balance, Shares at Dec. 31, 2021		10,990
Net loss	(13,433)
Ending Balance at Jun. 30, 2022	44,902	$ 110	135,819	(91,027)
Ending Balance, Shares at Jun. 30, 2022		11,021
Beginning Balance at Mar. 31, 2022	49,812	$ 110	133,970	(84,268)
Beginning Balance, Shares at Mar. 31, 2022		10,985
Issuance of common stock under the 2020 ESPP	212		212
Issuance of common stock under the 2020 ESPP, Shares		37
Restricted stock awards cancelled		(1)
Stock-based compensation	1,637		1,637
Net loss	(6,759)			(6,759)
Ending Balance at Jun. 30, 2022	$ 44,902	$ 110	$ 135,819	$ (91,027)
Ending Balance, Shares at Jun. 30, 2022		11,021

Overview and Basis of Presentat

Overview and Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Overview and Basis of Presentation	Note 1. Overview and Basis of Presentation Overview and Organization LENSAR, Inc. (“LENSAR” or the “Company”) is a global medical device business focused on the design, development and commercialization of advanced technology for the treatment of cataracts and management of astigmatism to achieve improved visual outcomes for patients. LENSAR is a public company whose stock is listed and trading under the symbol “LNSR” on The Nasdaq Stock Market LLC (“Nasdaq”). The Company’s revenue is derived from the sale and lease of LENSAR’s laser systems, which may include equipment, a consumable referred to as the Patient Interface Device (“PID”), procedure licenses, training, installation, limited warranty and maintenance agreements through extended warranty. LENSAR has developed its next-generation ALLY™ Adaptive Cataract Treatment System (“ALLY System”), the first platform to integrate its proprietary imaging with a dual-pulsed femtosecond laser and phacoemulsification technology in a single, compact system. The ALLY System, now cleared by the U.S. Food and Drug Administration (“FDA”), enables cataract surgeons to complete the femtosecond-laser-assisted cataract surgery (“FLACS”) procedure in a single, sterile environment. This clearance is the first stage of a planned, two step commercial release strategy. The Company expects to place between 8 and 12 systems in a controlled and targeted initial launch, with the first ALLY Systems being placed in the third quarter and continuing throughout the remainder of 2022. The ALLY System is expected to be made widely available to U.S. cataract surgeons in 2023. The Company’s ability to place systems in 2022 has been limited by supply chain constraints that have delayed the delivery of certain ALLY System raw materials and the completion and testing of ALLY Systems for use as launch-stock inventory. As the second stage of the commercial release strategy, the Company plans to seek an additional 510(k) clearance for the phacoemulsification features of the ALLY System in a subsequent 510(k) submission subject to a third party’s phacoemulsification device receiving clearance and serving as the predicate device. LENSAR was recently informed by the third party that it has withdrawn its 510(k) submission for its standalone phacoemulsification device and plans to resubmit the application at a later date. As this device will be considered the predicate device for purposes of evaluating the ALLY System’s phacoemulsification functionality, LENSAR is unable to submit its second 510(k) submission seeking clearance of the phacoemulsification features within the ALLY System until the predicate device receives FDA clearance. Accordingly, the Company will deliver the ALLY System to surgeons in the initial launch and the subsequent 2023 rollout with the phacoemulsification features remaining disabled and/or removed. The Company has incurred recurring losses and operating cash outflows since its inception and, as of June 30, 2022, had an accumulated deficit of $91,027. The Company expects to continue to incur losses and cash outflows from operating activities for the foreseeable future. In addition, the Company’s results of operations, financial condition and cash flows have been adversely affected by the COVID-19 pandemic, including supply chain shortages and price increases. The extent to which the COVID-19 outbreak, and current or future variants, will further negatively impact the Company’s business or operating results cannot be determined with certainty at this time. In geographies in which the Company or its customers, partners and service providers operate, health concerns as well as political or governmental developments in response to COVID-19 could result in further economic, social or labor instability or prolonged contractions in the industries in which the Company’s customers or partners operate, slow the sales process, result in customers not purchasing or renewing the Company’s products or failing to make payments, and could otherwise have a material adverse effect on the Company’s business and results of operations and financial condition. The Company has also experienced some supply chain disruptions, and increased costs of various component parts needed for the development of the ALLY System as a result of COVID-19, including increasing lead times required for the ordering of component parts to meet targeted production goals and unpredictability with respect to the availability and delivery timing of these parts. To date, the Company has maintained sufficient inventory to mitigate significant adverse impact from such disruptions and unavailability in the near-term and to facilitate the initial launch of the ALLY System assuming regulatory clearance; however, the Company is continuing to monitor developments with respect to such disruptions and their potential impact on the Company’s business, results of operations and financial condition. If these supply chain shortages and disruptions continue or worsen, or the Company is unable to find suitable alternative component parts, there is no guarantee the Company will be able to meet customer demand for the ALLY System following its initial launch. In addition, pricing increases in component parts for the ALLY System may necessitate an increase in overall cost to customers, which in turn may have an adverse impact on customer demand. Management believes the Company’s cash and cash equivalents on hand provide sufficient liquidity to meet the Company’s projected obligations for a period of at least twelve months from the date of issuance of these condensed financial statements. As the Company gets closer to the planned commercial launch of the ALLY System, anticipated to be in the third quarter of 2022, it expects annual revenue and selling, general and administrative expenses to increase from current levels. In addition, the successful commercialization of the ALLY System depends in part on the Company’s ability to produce the ALLY System in sufficient quantities and within requested timelines to satisfy customer demand. The Company expects cash and cash equivalents, together with cash generated from the sale and lease of products, to be sufficient to operate into 2024. The Company’s liquidity needs will be largely determined by the success of its operations regarding the successful commercialization of its existing products and the progression, additional regulatory clearance s and launch of the ALLY System in the future. Such success will depend on the availability of the necessary component parts for the ALLY S ystem. The Company expects it will need to raise additional capital through equity or debt financings or from other sources to continue its operations beyond 202 4 . The Company may issue securities, including common stock, preferred stock, warrants, and/or debt securities through private placement transactions or registered public offerings in the future. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of the Company’s control and the Company may be unable to raise financing when needed, or on terms favorable to the Company. If the necessary funds are not available from these sources, the Company may have to delay, reduce or suspend the scope of its sales and marketing efforts, research and development activities, or other components of its operations. Basis of Presentation These condensed financial statements of the Company are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information and, therefore, omit or condense certain footnotes and other information normally included. The condensed financial statements include all adjustments (consisting only of normal recurring adjustments), that management of the Company believes are necessary for a fair statement of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year. The December 31, 2021 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed financial statements and related financial information should be read in conjunction with the Company’s annual audited financial statements and the related notes thereto for the fiscal year ended December 31, 2021, included in the Annual Report on Form 10-K (the “Annual Report”) as filed with the SEC.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Other than policies noted below, there have been no significant changes to the significant accounting policies disclosed in Note 2, Summary of Significant Accounting Policies Accounting Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes to the condensed financial statements. The accounting estimates that require management’s most significant, difficult and subjective judgments include, but are not limited to, revenue recognition and allowance for expected credit losses, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, operating lease right-of-use assets and liabilities, and the recognition and measurement of current and deferred income tax assets and liabilities. Management evaluates its estimates on an ongoing basis as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates. The COVID-19 pandemic continues to directly and indirectly impact the Company’s business, results of operations and financial condition, including revenue, expenses, reserves and allowances. The Company continues to monitor developments that are highly uncertain, including supply chain disruptions and price increases, as well as the economic impact on domestic and international suppliers, customers, and markets. The Company assessed certain accounting matters that require consideration of forecasted financial information, including, but not limited to, its current expected credit losses, the carrying value of the Company's intangible assets and other long-lived assets, and valuation allowances in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2022 and through the date of this report. As a result of these assessments, there were no impairments or material increases in expected credit losses or valuation allowances that impacted the Company's condensed financial statements as of and for the three and six months ended June 30, 2022 and 2021. However, the Company's future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the condensed financial statements in future reporting periods. As of the date of issuance of these unaudited condensed interim financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Fair Value Measurement The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or the Company paid to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories: • Level 1—based on quoted market prices in active markets for identical assets and liabilities. • Level 2—based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable. Fair value measurements are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The carrying value of the Company’s cash, cash equivalents, accounts receivable, accounts payable, accrued liabilities, and other current liabilities approximate fair value based on the short-term maturities of these instruments. The carrying value of the Company’s notes receivable also approximates fair value based on the associated credit risk. Income Taxes Income tax expense/(benefit) from continuing operations for the three and six months ended June 30, 2022 and 2021 was $0 in each period, which resulted primarily from maintaining a full valuation allowance against the Company’s deferred tax assets. Recently Issued Accounting Pronouncements Not Yet Adopted The Company reviewed recent pronouncements issued by the FASB and other authoritative standards groups with future effective dates and concluded the pronouncements are either not applicable to the Company or are not expected to have a material impact on the Company’s financial position or results of operations.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Jun. 30, 2022
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	Note 3. Revenue from Contracts with Customers Disaggregation of Revenue The following table summarizes the Company’s product and service revenue disaggregated by geographic region, which is determined based on customer location, for the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 United States $ 4,097 $ 3,942 $ 8,067 $ 7,380 South Korea 662 1,190 2,096 2,188 Europe 956 921 2,575 1,810 Asia (excluding South Korea) 771 633 1,551 1,175 Other 137 96 275 161 Total 1 $ 6,623 $ 6,782 $ 14,564 $ 12,714 1 Leases Contract Balances The following table provides information about receivables and contract liabilities from contracts with customers: Classification As of June 30, 2022 As of December 31, 2021 Accounts receivable, current Accounts receivable, net $ 2,760 $ 4,638 Notes receivable, current Notes receivable, net $ 164 $ 350 Notes receivable, long-term Notes and other receivables, long-term, net $ 29 $ 121 Contract liability, current Deferred revenue $ 937 $ 904 Contract liability, non-current Other long-term liabilities $ 37 $ 66 Accounts Accounts receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. Most customers are on pre-paid or 30-day payment terms, depending on the product purchased. The Company maintains an allowance for expected credit losses to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer credit worthiness, historical payment experience, the age of outstanding receivables, collateral to the extent applicable and reflects the possible impact of current conditions and reasonable forecasts not already reflected in historical loss information. The following table summarizes the activity in the allowance for accounts receivable: Amount Accounts receivable, allowance for credit losses as of December 31, 2021 $ 47 Provision for credit losses (6 ) Write-offs (16 ) Accounts receivable, allowance for credit losses as of June 30, 2022 $ 25 Accounts receivable, allowance for credit losses as of December 31, 2020 $ 19 Provision for credit losses 8 Write-offs — Accounts receivable, allowance for credit losses as of June 30, 2021 $ 27 Notes Receivables, Net – Notes receivable, net includes amounts billed and due from customers under extended payment terms with a significant financing component. Interest rates on notes receivable range from 5.0% to 5.75%. The Company recorded interest income on notes receivable during the three months ended June 30, 2022 and 2021 of $3 and $9, respectively, and during the six months ended June 30, 2022 and 2021 of $8 and $19, respectively, in other income, net in the statement of operations. The following table summarizes the activity in the allowance for notes receivable: Amount Notes receivable, allowance for credit losses as of December 31, 2021 $ 63 Provision for credit losses 130 Write-offs (11 ) Notes receivable, allowance for credit losses as of June 30, 2022 $ 182 Notes receivable, allowance for credit losses as of December 31, 2020 $ 18 Provision for credit losses (3 ) Write-offs — Notes receivable, allowance for credit losses as of June 30, 2021 $ 15 Contract Liabilities – The Company’s contract liabilities consist of deferred revenue related to services and products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in other long-term liabilities in the Company’s condensed balance sheets. The following table provides information about contract liabilities from contracts with customers: Amount Contract liabilities as of December 31, 2021 $ 970 Billings not yet recognized as revenue 637 Beginning contract liabilities recognized as revenue (633 ) Contract liabilities as of June 30, 2022 $ 974 Contract liabilities as of December 31, 2020 $ 1,051 Billings not yet recognized as revenue 713 Beginning contract liabilities recognized as revenue (622 ) Contract liabilities as of June 30, 2021 $ 1,142 Transaction Price Allocated to Future Performance Obligations At June 30, 2022, the revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more was approximately $4,830. The Company expects to satisfy its remaining performance obligations by December 31, 2026, with $2,433 to be satisfied by December 31, 2022, $1,907 to be satisfied by December 31, 2023, $309 to be satisfied by December 31, 2024 and $181 to be satisfied thereafter. The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for the products delivered or services performed.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories	Note 4. Inventories Inventory balances were as follows: As of June 30, 2022 As of December 31, 2021 Finished Goods $ 1,884 $ 4,319 Work-in-process 273 173 Raw Materials 3,699 1,996 Total $ 5,856 $ 6,488

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Note 5. Leases Lessor Arrangements The Company has operating leases for the LENSAR Laser System. The Company’s leases have remaining lease terms of less than one year to four years. Lease revenue for the three and six months ended June 30, 2022 and 2021 was as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Lease revenue $ 1,415 $ 1,140 $ 2,814 $ 2,251

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 6. Intangible Assets The components of intangible assets were as follows: As of June 30, 2022 As of December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Finite-lived intangible assets: Customer relationships 1,2 $ 4,292 $ (1,860 ) $ 2,432 $ 4,292 $ (1,685 ) $ 2,607 Acquired technology 1,3,4 13,900 (3,658 ) 10,242 11,500 (3,275 ) 8,225 Acquired trademarks 1 570 (570 ) — 570 (532 ) 38 $ 18,762 $ (6,088 ) $ 12,674 $ 16,362 $ (5,492 ) $ 10,870 1 Certain intangible assets were established upon PDL BioPharma, Inc.’s acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a period of 15 years. The intangible assets for customer relationships are amortized on a straight-line basis or a double declining basis over their estimated useful lives up to 20 years based on the method that better represents the economic benefits to be obtained. 2 LENSAR acquired certain intangible assets for customer relationships from a domestic distributor in an asset acquisition, which are being amortized on a straight-line basis over a period of 10 years. 3 LENSAR acquired certain intangible assets from a medical technology company in an asset acquisition, which are being amortized on a straight-line basis over a period of 15 years. 4 In 2019, LENSAR acquired certain intellectual property from a third-party. In connection with the agreement, milestone payments of $2,400 were contingent upon regulatory approval and commercialization of the ALLY System. Refer to Note 8, Commitments and Contingencies, Amortization expense for three months ended June 30, 2022 and 2021 was $287 and $309, respectively, and for the six months ended June 30, 2022 and 2021 was $596 and $622, respectively. Based on the intangible assets recorded at June 30, 2022, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows: Fiscal Year Amount Remainder of 2022 2,953 2023 1,097 2024 1,085 2025 1,074 2026 1,064 2027 1,055 Thereafter 4,346 Total remaining estimated amortization expense $ 12,674

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2022
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consist of the following: As of June 30, 2022 As of December 31, 2021 Compensation $ 2,320 $ 3,375 Professional services 1,173 526 Customer advances 395 159 Warranty 21 45 Other 463 499 Total $ 4,372 $ 4,604

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8. Commitments and Contingencies Purchase Obligation LENSAR is a party to various supply agreements for the manufacture and supply of certain components. The supply agreements commit LENSAR to a minimum purchase obligation of approximately $7,815 by December 31, 2023. LENSAR expects to meet these requirements. Royalty and Milestone Payments In connection with the acquisition of certain intellectual property, the Company paid a $1,200 milestone payment, which was contingent upon regulatory clearance of the ALLY System. The Company could also be required to make an additional milestone payment in the amount of $1,200, which is contingent upon the commercialization of the ALLY System Legal Matters The medical device market in which LENSAR participates is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Management believes that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on the Company’s results of operations, financial condition or cash flows.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders' Equity	Note 9. Stockholders’ Equity Preferred Stock The Company has a single class of preferred stock, of which no shares were issued and outstanding. Common Stock The Company has a single class of common stock in which stockholders are entitled to one vote for each share of common stock. No cash dividend was declared on common stock during the three and six months ended June 30, 2022 and 2021.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Note 10. Stock-Based Compensation Stock-Based Incentive The 2020 Plan In July 2020, the Board of Directors approved the LENSAR Inc. 2020 Incentive Award Plan (the “2020 Plan”). The 2020 Plan provides for the grant of stock options, restricted stock, restricted stock unit awards and other stock-based awards to recipients. The amount and terms of grants are determined by the Company’s Board of Directors or a duly authorized committee thereof. Participants must pay the Company, or make provisions to pay, any required withholding taxes by the date of the event creating the tax liability. Participants may satisfy the tax liability in cash or in stock. A total of 3,333 shares of common stock were initially reserved for issuance pursuant to the 2020 Plan. The number of shares available for issuance under the 2020 Plan includes an annual increase on the first day of each fiscal year beginning fiscal 2021, equal to the lesser of (i) 5% of the aggregate number of shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as determined by the Board of Directors. As of June 30, 2022 the Company has reserved 4,429 shares of common stock for issuance under the 2020 Plan. A summary of the shares available for issuance under the 2020 Plan is as follows: Number of Shares Balance at December 31, 2021 1,082 Authorized 549 Granted/Awarded (660 ) Cancelled 40 Balance at June 30, 2022 1,011 Stock Options The exercise price of incentive stock options (“ISOs”) and nonqualified stock options (“NSOs”) shall not be less than 100% of the fair market value on the grant date of the option and the term may not exceed 10 years. The exercise price of ISOs granted to a 10% stockholder shall not be less than 110% of the estimated fair market value on the grant date of the option and the term may not exceed five years. To date, options have a term of 10 years and generally vest over one to four years from the grant date. Option award activity under the 2020 Plan is set forth below: Options Outstanding Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value Outstanding at December 31, 2021 653 $ 7.57 9.3 $ — Options granted 574 $ 6.20 Options exercised — $ — Options cancelled (34 ) $ 6.87 Outstanding at June 30, 2022 1,193 $ 6.93 9.2 $ 215 Vested and expected to vest at June 30, 2022 1,193 $ 6.93 9.2 $ 215 Vested and exercisable at June 30, 2022 311 $ 7.54 8.8 $ — The weighted average grant date fair value of options granted during the three and six months ended June 30, 2022 was $4.48 and $3.90, respectively. The total fair value of options vested during the three and six months ended June 30, 2022 was approximately $503 and $1,050, respectively. Total unrecognized compensation expense of $3,490 related to stock options will be recognized over a weighted average period of 2.9 years. The Company estimated the fair value of stock-options using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of stock options was estimated using the following assumptions for the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Risk-free interest rate 2.5 - 3.0% 1.1% 1.5 - 3.0% 0.6 - 1.1% Expected term (years) 6 6 6 6 Expected volatility 70% 73% 70% 72 - 73% Dividends 0.0% 0.0% 0.0% 0.0% Expected term : The expected term for the Company’s stock-based compensation awards was based on an index of the expected terms of a group of comparable publicly-traded medical device and other peer companies, which the Company believed was representative of the expected term of its awards. Risk-free interest rate : The risk-free interest rate was based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected term. Expected volatility : The expected volatility for the Company’s stock-based compensation awards was based on an index of the historical volatilities of a group of comparable publicly-traded medical device and other peer companies, which the Company believed was representative of the volatility of its common stock. Expected dividend yield : The Company does not intend to pay dividends for the foreseeable future. Accordingly, the Company used a dividend yield of zero in the assumptions Restricted Stock Awards Restricted stock has the same rights as other issued and outstanding shares of the Company’s common stock. The compensation expense related to these awards is determined using the fair market value of the Company’s common stock on the date of the grant. Under the Company’s restricted stock plans, restricted stock awards typically vest over three years and compensation expense associated with these awards is recognized on a straight-line basis over the vesting period. Restricted stock award activity under the 2020 Plan is set forth below: Restricted Stock Awards Outstanding Number of Units Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2021 1,332 $ 10.29 Restricted stock awards granted — $ — Restricted stock awards vested (478 ) $ 10.33 Restricted stock awards cancelled (6 ) $ 10.81 Non-vested at June 30, 2022 848 $ 10.27 The total fair value of restricted stock awards vested during the three and six months ended June 30, 2022 was approximately $1,421 and $4,933, respectively. At June 30, 2022 there was approximately $5,129 of total unrecognized compensation expense related to restricted stock awards, which is expected to be recognized over a weighted-average period of 1.1 years. The number of restricted stock awards that are expected to vest are as follows: 113 in the quarter ending September 30, 2022; 113 in the quarter ending December 31, 2022; 237 in the quarter ending March 31, 2023; 136 in the quarter ending June 30, 2023; 174 in the quarter ending September 30, 2023; and 75 in the quarter ending December 31, 2023. These are based on restricted stock awards outstanding at June 30, 2022 and assumes the requisite service period is fulfilled for all awards outstanding. Actual vesting in future periods may vary from those reflected above. Restricted Stock Units Restricted stock units granted to employees generally vest over four years in annual equal increments. The fair value of restricted stock units is based on the Company’s closing stock price on the date of grant. Restricted stock unit activity under the 2020 Plan is set forth below: Restricted Stock Units Outstanding Number of Units Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2021 — $ — Restricted stock units granted 86 $ 6.33 Restricted stock units vested — $ — Restricted stock units cancelled — $ — Non-vested at June 30, 2022 86 $ 6.33 At June 30, 2022 there was approximately $482 of total unrecognized compensation expense related to restricted stock units, which is expected to be recognized over a weighted-average period of 2.7 years. 2020 Employee Stock Purchase Plan In September 2020, the Board of Directors approved the LENSAR, Inc. 2020 Employee Stock Purchase Plan (the “2020 ESPP”), under which eligible employees are permitted to purchase common stock at a discount through payroll deductions. A total of 340 shares of common stock are reserved for issuance and will be increased on the first day of each fiscal year, beginning in 2022, by an amount equal to the lesser of (i) 1.0% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (ii) a lesser amount as determined by the Board of Directors. The price of the common stock purchased will be the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. The 2020 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section 423 of the IRC. As of June 30, 2022, 94 shares of common stock have been issued to employees participating in the 2020 ESPP and 246 shares were available for future issuance under the 2020 ESPP. The grant date fair value of the shares to be issued under the Company’s 2020 ESPP was estimated using the Black-Scholes valuation model. The following table sets forth the total stock-based compensation expense recognized under the 2020 Plan and the 2020 ESPP in the Company’s condensed statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of revenue – product $ 54 $ 47 $ 106 $ 122 Cost of revenue – service 32 27 62 68 Selling, general and administrative expenses 1,397 1,223 2,774 3,207 Research and development expenses 154 133 302 353 Total $ 1,637 $ 1,430 $ 3,244 $ 3,750 Total unrecognized stock-based compensation expense is expected to be amortized as follows: Fiscal Year Amount 2022 $ 3,263 2023 4,218 2024 981 2025 625 2026 14 Thereafter — Total unrecognized stock-based compensation expense $ 9,101 The amounts included in this table are based on restricted stock awards, restricted stock units, and stock options outstanding at June 30, 2022 and assumes the requisite service period is fulfilled for all awards outstanding. Actual stock-based compensation expense in future periods may vary from those reflected in the table.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Share	Note 11. Net Loss per Share The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted net loss per share calculations: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net loss $ (6,759 ) $ (4,362 ) $ (13,433 ) $ (9,544 ) Weighted average number of shares of common stock 10,073 9,296 10,020 9,242 Basic and diluted net loss per share $ (0.67 ) $ (0.47 ) $ (1.34 ) $ (1.03 ) The Company’s basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. As the Company has reported a net loss for all periods presented, basic and diluted net loss per share attributable to common stockholders are the same for those periods. The Company excluded 934 shares of underlying unvested restricted stock awards and units and 1,193 outstanding stock options for the three and six months ended June 30, 2022 and 1,573 shares of underlying unvested restricted stock awards and 629 outstanding stock options for the three and six months ended June 30, 2021 from its net loss per diluted share calculations because their effect was anti-dilutive. The anti-dilutive weighted average shares excluded from the diluted net loss per share diluted shares calculations were: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Restricted stock awards and units 995 1,417 1,033 1,431 Outstanding stock options 1,140 537 1,096 328 Total 2,135 1,954 2,129 1,759

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Accounting Estimates	Accounting Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes to the condensed financial statements. The accounting estimates that require management’s most significant, difficult and subjective judgments include, but are not limited to, revenue recognition and allowance for expected credit losses, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, operating lease right-of-use assets and liabilities, and the recognition and measurement of current and deferred income tax assets and liabilities. Management evaluates its estimates on an ongoing basis as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates. The COVID-19 pandemic continues to directly and indirectly impact the Company’s business, results of operations and financial condition, including revenue, expenses, reserves and allowances. The Company continues to monitor developments that are highly uncertain, including supply chain disruptions and price increases, as well as the economic impact on domestic and international suppliers, customers, and markets. The Company assessed certain accounting matters that require consideration of forecasted financial information, including, but not limited to, its current expected credit losses, the carrying value of the Company's intangible assets and other long-lived assets, and valuation allowances in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2022 and through the date of this report. As a result of these assessments, there were no impairments or material increases in expected credit losses or valuation allowances that impacted the Company's condensed financial statements as of and for the three and six months ended June 30, 2022 and 2021. However, the Company's future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the condensed financial statements in future reporting periods. As of the date of issuance of these unaudited condensed interim financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities.
Fair Value Measurement	Fair Value Measurement The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or the Company paid to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories: • Level 1—based on quoted market prices in active markets for identical assets and liabilities. • Level 2—based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable. Fair value measurements are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The carrying value of the Company’s cash, cash equivalents, accounts receivable, accounts payable, accrued liabilities, and other current liabilities approximate fair value based on the short-term maturities of these instruments. The carrying value of the Company’s notes receivable also approximates fair value based on the associated credit risk.
Income Taxes	Income Taxes Income tax expense/(benefit) from continuing operations for the three and six months ended June 30, 2022 and 2021 was $0 in each period, which resulted primarily from maintaining a full valuation allowance against the Company’s deferred tax assets.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted The Company reviewed recent pronouncements issued by the FASB and other authoritative standards groups with future effective dates and concluded the pronouncements are either not applicable to the Company or are not expected to have a material impact on the Company’s financial position or results of operations.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue From Contract With Customer [Abstract]
Summary of Product and Service Revenue Disaggregated by Geographic Region	The following table summarizes the Company’s product and service revenue disaggregated by geographic region, which is determined based on customer location, for the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 United States $ 4,097 $ 3,942 $ 8,067 $ 7,380 South Korea 662 1,190 2,096 2,188 Europe 956 921 2,575 1,810 Asia (excluding South Korea) 771 633 1,551 1,175 Other 137 96 275 161 Total 1 $ 6,623 $ 6,782 $ 14,564 $ 12,714 1 Leases
Summary of Information about Receivables and Contract Liabilities from Contracts with Customers	The following table provides information about receivables and contract liabilities from contracts with customers: Classification As of June 30, 2022 As of December 31, 2021 Accounts receivable, current Accounts receivable, net $ 2,760 $ 4,638 Notes receivable, current Notes receivable, net $ 164 $ 350 Notes receivable, long-term Notes and other receivables, long-term, net $ 29 $ 121 Contract liability, current Deferred revenue $ 937 $ 904 Contract liability, non-current Other long-term liabilities $ 37 $ 66 The following table provides information about contract liabilities from contracts with customers: Amount Contract liabilities as of December 31, 2021 $ 970 Billings not yet recognized as revenue 637 Beginning contract liabilities recognized as revenue (633 ) Contract liabilities as of June 30, 2022 $ 974 Contract liabilities as of December 31, 2020 $ 1,051 Billings not yet recognized as revenue 713 Beginning contract liabilities recognized as revenue (622 ) Contract liabilities as of June 30, 2021 $ 1,142
Summary of Allowance for Accounts Receivable	The following table summarizes the activity in the allowance for accounts receivable: Amount Accounts receivable, allowance for credit losses as of December 31, 2021 $ 47 Provision for credit losses (6 ) Write-offs (16 ) Accounts receivable, allowance for credit losses as of June 30, 2022 $ 25 Accounts receivable, allowance for credit losses as of December 31, 2020 $ 19 Provision for credit losses 8 Write-offs — Accounts receivable, allowance for credit losses as of June 30, 2021 $ 27
Summary of Allowance for Notes Receivable	The following table summarizes the activity in the allowance for notes receivable: Amount Notes receivable, allowance for credit losses as of December 31, 2021 $ 63 Provision for credit losses 130 Write-offs (11 ) Notes receivable, allowance for credit losses as of June 30, 2022 $ 182 Notes receivable, allowance for credit losses as of December 31, 2020 $ 18 Provision for credit losses (3 ) Write-offs — Notes receivable, allowance for credit losses as of June 30, 2021 $ 15

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory balances were as follows: As of June 30, 2022 As of December 31, 2021 Finished Goods $ 1,884 $ 4,319 Work-in-process 273 173 Raw Materials 3,699 1,996 Total $ 5,856 $ 6,488

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule of Lease Revenue	Lease revenue for the three and six months ended June 30, 2022 and 2021 was as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Lease revenue $ 1,415 $ 1,140 $ 2,814 $ 2,251

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Components of Intangible Assets	The components of intangible assets were as follows: As of June 30, 2022 As of December 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Finite-lived intangible assets: Customer relationships 1,2 $ 4,292 $ (1,860 ) $ 2,432 $ 4,292 $ (1,685 ) $ 2,607 Acquired technology 1,3,4 13,900 (3,658 ) 10,242 11,500 (3,275 ) 8,225 Acquired trademarks 1 570 (570 ) — 570 (532 ) 38 $ 18,762 $ (6,088 ) $ 12,674 $ 16,362 $ (5,492 ) $ 10,870 1 Certain intangible assets were established upon PDL BioPharma, Inc.’s acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a period of 15 years. The intangible assets for customer relationships are amortized on a straight-line basis or a double declining basis over their estimated useful lives up to 20 years based on the method that better represents the economic benefits to be obtained. 2 LENSAR acquired certain intangible assets for customer relationships from a domestic distributor in an asset acquisition, which are being amortized on a straight-line basis over a period of 10 years. 3 LENSAR acquired certain intangible assets from a medical technology company in an asset acquisition, which are being amortized on a straight-line basis over a period of 15 years. 4 In 2019, LENSAR acquired certain intellectual property from a third-party. In connection with the agreement, milestone payments of $2,400 were contingent upon regulatory approval and commercialization of the ALLY System. Refer to Note 8, Commitments and Contingencies,
Schedule of Impairment of Underlying Assets, Remaining Amortization Expense	Based on the intangible assets recorded at June 30, 2022, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows: Fiscal Year Amount Remainder of 2022 2,953 2023 1,097 2024 1,085 2025 1,074 2026 1,064 2027 1,055 Thereafter 4,346 Total remaining estimated amortization expense $ 12,674

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Accrued Liabilities Current [Abstract]
Schedule of Accrued Liabilities	As of June 30, 2022 As of December 31, 2021 Compensation $ 2,320 $ 3,375 Professional services 1,173 526 Customer advances 395 159 Warranty 21 45 Other 463 499 Total $ 4,372 $ 4,604

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Shares Available for Issuance Under 2020 Plan	A summary of the shares available for issuance under the 2020 Plan is as follows: Number of Shares Balance at December 31, 2021 1,082 Authorized 549 Granted/Awarded (660 ) Cancelled 40 Balance at June 30, 2022 1,011
Summary of Option Award Activity	Option award activity under the 2020 Plan is set forth below: Options Outstanding Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value Outstanding at December 31, 2021 653 $ 7.57 9.3 $ — Options granted 574 $ 6.20 Options exercised — $ — Options cancelled (34 ) $ 6.87 Outstanding at June 30, 2022 1,193 $ 6.93 9.2 $ 215 Vested and expected to vest at June 30, 2022 1,193 $ 6.93 9.2 $ 215 Vested and exercisable at June 30, 2022 311 $ 7.54 8.8 $ —
Summary of Fair Value of Stock Options was Estimated Using Assumptions	The Company estimated the fair value of stock-options using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of stock options was estimated using the following assumptions for the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Risk-free interest rate 2.5 - 3.0% 1.1% 1.5 - 3.0% 0.6 - 1.1% Expected term (years) 6 6 6 6 Expected volatility 70% 73% 70% 72 - 73% Dividends 0.0% 0.0% 0.0% 0.0%
Summary of Total Stock-Based Compensation Expense Recognized	The following table sets forth the total stock-based compensation expense recognized under the 2020 Plan and the 2020 ESPP in the Company’s condensed statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cost of revenue – product $ 54 $ 47 $ 106 $ 122 Cost of revenue – service 32 27 62 68 Selling, general and administrative expenses 1,397 1,223 2,774 3,207 Research and development expenses 154 133 302 353 Total $ 1,637 $ 1,430 $ 3,244 $ 3,750
Summary of Unrecognized Stock-based Compensation Expense Expected to be Amortized	Total unrecognized stock-based compensation expense is expected to be amortized as follows: Fiscal Year Amount 2022 $ 3,263 2023 4,218 2024 981 2025 625 2026 14 Thereafter — Total unrecognized stock-based compensation expense $ 9,101
Restricted Stock Awards
Summary of Restricted Stock Award and Restricted Stock Units Activity	Restricted stock award activity under the 2020 Plan is set forth below: Restricted Stock Awards Outstanding Number of Units Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2021 1,332 $ 10.29 Restricted stock awards granted — $ — Restricted stock awards vested (478 ) $ 10.33 Restricted stock awards cancelled (6 ) $ 10.81 Non-vested at June 30, 2022 848 $ 10.27
Restricted Stock Units
Summary of Restricted Stock Award and Restricted Stock Units Activity	Restricted stock units granted to employees generally vest over four years in annual equal increments. The fair value of restricted stock units is based on the Company’s closing stock price on the date of grant. Restricted stock unit activity under the 2020 Plan is set forth below: Restricted Stock Units Outstanding Number of Units Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2021 — $ — Restricted stock units granted 86 $ 6.33 Restricted stock units vested — $ — Restricted stock units cancelled — $ — Non-vested at June 30, 2022 86 $ 6.33

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share	The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted net loss per share calculations: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net loss $ (6,759 ) $ (4,362 ) $ (13,433 ) $ (9,544 ) Weighted average number of shares of common stock 10,073 9,296 10,020 9,242 Basic and diluted net loss per share $ (0.67 ) $ (0.47 ) $ (1.34 ) $ (1.03 )
Schedule of Anti-Dilutive Weighted Average Shares Excluded From Diluted Net Loss Per Share Diluted Shares Calculation	The anti-dilutive weighted average shares excluded from the diluted net loss per share diluted shares calculations were: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Restricted stock awards and units 995 1,417 1,033 1,431 Outstanding stock options 1,140 537 1,096 328 Total 2,135 1,954 2,129 1,759

Overview and Basis of Present_2

Overview and Basis of Presentation - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ (91,027)	$ (77,594)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Accounting Policies [Abstract]
Income tax expense/(benefit) from continuing operations	$ 0	$ 0	$ 0	$ 0

Revenue From Contracts With C_3

Revenue From Contracts With Customers - Summary of Product and Service Revenue Disaggregated by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Product and service revenue	$ 6,623	$ 6,782	$ 14,564	$ 12,714
United States
Disaggregation Of Revenue [Line Items]
Product and service revenue	4,097	3,942	8,067	7,380
South Korea
Disaggregation Of Revenue [Line Items]
Product and service revenue	662	1,190	2,096	2,188
Europe
Disaggregation Of Revenue [Line Items]
Product and service revenue	956	921	2,575	1,810
Asia (Excluding South Korea)
Disaggregation Of Revenue [Line Items]
Product and service revenue	771	633	1,551	1,175
Other
Disaggregation Of Revenue [Line Items]
Product and service revenue	$ 137	$ 96	$ 275	$ 161

Revenue From Contracts With C_4

Revenue From Contracts With Customers - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue From Contracts With Customers [Line Items]
Lease revenue	$ 1,415	$ 1,140	$ 2,814	$ 2,251
Accounts receivables payment terms			30 days
Revenue remaining performance obligation amount	4,830		$ 4,830
Other Income, Net
Revenue From Contracts With Customers [Line Items]
Interest income on notes receivable	$ 3	$ 9	$ 8	$ 19
Minimum
Revenue From Contracts With Customers [Line Items]
Notes receivable interest rate	5%		5%
Maximum
Revenue From Contracts With Customers [Line Items]
Notes receivable interest rate	5.75%		5.75%

Revenue From Contracts With C_5

Revenue From Contracts With Customers - Summary of Information about Receivables and Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Contract Balances [Line Items]
Accounts receivable, current	$ 2,760	$ 4,638
Notes receivable, current	164	350
Notes receivable, long-term	29	121
Contract liability, current	937	904
Notes and Other Receivables, Long-Term, Net
Schedule Of Contract Balances [Line Items]
Notes receivable, long-term	29	121
Deferred Revenue
Schedule Of Contract Balances [Line Items]
Contract liability, current	937	904
Other Long-Term Liabilities
Schedule Of Contract Balances [Line Items]
Contract liability, non-current	$ 37	$ 66

Revenue From Contracts With C_6

Revenue From Contracts With Customers - Summary of Allowance for Accounts Receivable (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Revenue From Contract With Customer [Abstract]
Beginning balance	$ 47	$ 19
Provision for credit losses	(6)	8
Write-offs	(16)
Ending balance	$ 25	$ 27

Revenue From Contracts With C_7

Revenue From Contracts With Customers - Summary of Allowance for Notes Receivable (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	$ 63	$ 18
Provision for credit losses	130	(3)
Write-offs	(11)
Ending balance	$ 182	$ 15

Revenue From Contracts With C_8

Revenue From Contracts With Customers - Schedule of Information About Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Revenue From Contract With Customer [Abstract]
Beginning balance	$ 970	$ 1,051
Billings not yet recognized as revenue	637	713
Beginning contract liabilities recognized as revenue	(633)	(622)
Ending balance	$ 974	$ 1,142

Revenue From Contracts With C_9

Revenue From Contracts With Customers - Additional Information (Details 1) $ in Thousands	Jun. 30, 2022 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 4,830
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 2,433
Revenue remaining performance obligation expected timing of satisfaction period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 1,907
Revenue remaining performance obligation expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 309
Revenue remaining performance obligation expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 181
Revenue remaining performance obligation expected timing of satisfaction period	1 year

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Net [Abstract]
Finished Goods	$ 1,884	$ 4,319
Work-in-process	273	173
Raw Materials	3,699	1,996
Total	$ 5,856	$ 6,488

Leases - Additional Information

Leases - Additional Information (Details)	Jun. 30, 2022
Minimum
Lessor Lease Description [Line Items]
Lessor, operating leases, remaining lease terms	1 year
Maximum
Lessor Lease Description [Line Items]
Lessor, operating leases, remaining lease terms	4 years

Leases - Schedule of Lease Reve

Leases - Schedule of Lease Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Lease revenue	$ 1,415	$ 1,140	$ 2,814	$ 2,251

Intangible Assets - Components

Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 18,762	$ 16,362
Accumulated Amortization	(6,088)	(5,492)
Net Carrying Amount	12,674	10,870
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,292	4,292
Accumulated Amortization	(1,860)	(1,685)
Net Carrying Amount	2,432	2,607
Acquired Technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	13,900	11,500
Accumulated Amortization	(3,658)	(3,275)
Net Carrying Amount	10,242	8,225
Acquired Trademarks
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	570	570
Accumulated Amortization	$ (570)	(532)
Net Carrying Amount		$ 38

Intangible Assets - Component_2

Intangible Assets - Components of Intangible Assets (Parenthetical) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets weighted average amortization period	15 years	15 years
Contingent milestone payments		$ 2,400
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets weighted average amortization period	10 years
Acquired Technology
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets weighted average amortization period	15 years
Maximum | Customer Relationships
Finite Lived Intangible Assets [Line Items]
Intangible assets estimated useful life	20 years

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 287	$ 309	$ 596	$ 622

Intangible Assets - Schedule of

Intangible Assets - Schedule of Impairment of Underlying Assets, Remaining Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
Remainder of 2022	$ 2,953
2023	1,097
2024	1,085
2025	1,074
2026	1,064
2027	1,055
Thereafter	4,346
Net Carrying Amount	$ 12,674	$ 10,870

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accrued Liabilities Current [Abstract]
Compensation	$ 2,320	$ 3,375
Professional services	1,173	526
Customer advances	395	159
Warranty	21	45
Other	463	499
Total	$ 4,372	$ 4,604

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Commitments And Contingencies Disclosure [Line Items]
Contingent milestone payments upon regulatory clearance	$ 1,200
Contingent additional milestone payments upon commercialization	$ 1,200
Additional royalty payments rate	3%
Supply Agreement
Commitments And Contingencies Disclosure [Line Items]
Purchase obligation	$ 7,815

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Equity [Abstract]
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock voting rights		The Company has a single class of common stock in which stockholders are entitled to one vote for each share of common stock
Cash dividend declared on common stock	$ 0	$ 0

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

Jul. 31, 2020

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Dec. 31, 2023

Sep. 30, 2023

Jun. 30, 2023

Mar. 31, 2023

Dec. 31, 2022

Sep. 30, 2022

Mar. 31, 2022

Dec. 31, 2021

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Weighted average grant date fair value of options granted

$ 4.48

$ 3.90

Total fair value of options vested

$ 503

$ 1,050

Total unrecognized compensation expense

$ 3,490

$ 3,490

Total unrecognized compensation expense, weighted-average period of recognition

2 years 10 months 24 days

Dividends

0%

0%

0%

0%

Common stock, shares authorized

150,000,000

150,000,000

150,000,000

2020 Employee Stock Purchase Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Percentage of outstanding shares of common stock

1%

Exercise price of option on fair value (as a percent)

85%

Common stock, shares authorized

340,000

340,000

Incentive Stock Options | Share-based Payment Arrangement, Tranche Two

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Award vesting percentage

10%

Restricted Stock Awards

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total unrecognized compensation expense, weighted-average period of recognition

1 year 1 month 6 days

Total fair value of restricted stock awards vested

$ 1,421

$ 4,933

Total unrecognized compensation expense

5,129

$ 5,129

Restricted Stock Awards | Forecast

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of restricted stock awards are expected to vest

75,000

174,000

136,000

237,000

113,000

113,000

Minimum | Incentive Stock Options And Nonqualified Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period

1 year

Minimum | Incentive Stock Options And Nonqualified Stock Options | Share-based Payment Arrangement, Tranche One

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Exercise price of option on fair value (as a percent)

100%

Minimum | Incentive Stock Options | Share-based Payment Arrangement, Tranche Two

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Exercise price of option on fair value (as a percent)

110%

Maximum | Incentive Stock Options And Nonqualified Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Term of contract

10 years

Vesting period

4 years

Maximum | Incentive Stock Options And Nonqualified Stock Options | Share-based Payment Arrangement, Tranche One

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Term of contract

10 years

Maximum | Incentive Stock Options | Share-based Payment Arrangement, Tranche Two

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Term of contract

5 years

2020 Incentive Award Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common stock reserved for issuance

3,333,000

4,429,000

Percentage of outstanding shares of common stock

5%

2020 Incentive Award Plan | Restricted Stock Units

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total unrecognized compensation expense

$ 482

$ 482

Total unrecognized compensation expense, weighted-average period of recognition

2 years 8 months 12 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Shares Available for Issuance Under 2020 Plan (Details) - 2020 Incentive Award Plan	6 Months Ended
	Jun. 30, 2022 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Balances	1,082,000
Authorized	549,000
Granted/Awarded	(660,000)
Cancelled	40,000
Balances	1,011,000

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Option Award Activity (Details) - 2020 Incentive Award Plan - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at December 31, 2021	653,000
Options granted	574,000
Options cancelled	(34,000)
Outstanding at June 30, 2022	1,193,000	653,000
Vested and expected to vest at June 30, 2022	1,193,000
Vested and exercisable at June 30, 2022	311,000
Outstanding at beginning of period, Weighted Average Exercise Price	$ 7.57
Options granted, Weighted Average Exercise Price	6.20
Options cancelled, Weighted Average Exercise Price	6.87
Outstanding at end of period, Weighted Average Exercise Price	6.93	$ 7.57
Vested and expected to vest at March 31, 2022, Weighted Average Exercise Price	6.93
Vested and exercisable at March 31, 2022, Weighted Average Exercise Price	$ 7.54
Options Outstanding, Weighted Average Remaining Contractual Term (in Years)	9 years 2 months 12 days	9 years 3 months 18 days
Vested and expected to vest at March 31, 2022, Weighted Average Remaining Contractual Term (in Years)	9 years 2 months 12 days
Vested and exercisable at March 31, 2022, Weighted Average Remaining Contractual Term (in Years)	8 years 9 months 18 days
Outstanding at March 31, 2022, Aggregate Intrinsic Value	$ 215
Vested and expected to vest at March 31, 2022, Aggregate Intrinsic Value	$ 215

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Fair Value of Employee and Non-Employee Stock Options was Estimated Using Assumptions (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rate		1.10%
Risk-free interest rate, minimum	2.50%		1.50%	0.60%
Risk-free interest rate, maximum	3%		3%	1.10%
Expected term (years)	6 years	6 years	6 years	6 years
Expected volatility	70%	73%	70%
Expected volatility, minimum				72%
Expected volatility, maximum				73%
Dividends	0%	0%	0%	0%

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Restricted Stock Award Activity (Details) - Restricted Stock Awards - 2020 Incentive Award Plan shares in Thousands	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested at December 31, 2021 | shares	1,332
Restricted stock awards vested | shares	(478)
Restricted stock awards cancelled | shares	(6)
Non-vested at June 30, 2022 | shares	848
Non-vested at December 31, 2021 | $ / shares	$ 10.29
Restricted stock awards vested | $ / shares	10.33
Restricted stock awards cancelled | $ / shares	10.81
Non-vested at June 30, 2022 | $ / shares	$ 10.27

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units - 2020 Incentive Award Plan shares in Thousands	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock awards granted | shares	86
Non-vested at June 30, 2022 | shares	86
Restricted stock awards granted | $ / shares	$ 6.33
Non-vested at June 30, 2022 | $ / shares	$ 6.33

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,637	$ 1,430	$ 3,244	$ 3,750
Cost of Sales | Product
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	54	47	106	122
Cost of Sales | Service
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	32	27	62	68
Selling, General and Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,397	1,223	2,774	3,207
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 154	$ 133	$ 302	$ 353

Stock-Based Compensation - Su_7

Stock-Based Compensation - Summary of Unrecognized Stock-based Compensation Expense Expected to be Amortized (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
2022	$ 3,263
2023	4,218
2024	981
2025	625
2026	14
Total unrecognized stock-based compensation expense	$ 9,101

Net Loss per Share - Reconcilia

Net Loss per Share - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net loss	$ (6,759)	$ (4,362)	$ (13,433)	$ (9,544)
Weighted average number of shares of common stock	10,073	9,296	10,020	9,242
Weighted average number of shares of common stock	10,073	9,296	10,020	9,242
Basic net loss per share	$ (0.67)	$ (0.47)	$ (1.34)	$ (1.03)
Diluted net loss per share	$ (0.67)	$ (0.47)	$ (1.34)	$ (1.03)

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Restricted Stock Awards and Units
Earnings Per Share Basic [Line Items]
Shares excluded from the calculation of net loss per diluted share	934		934
Restricted Stock Awards
Earnings Per Share Basic [Line Items]
Shares excluded from the calculation of net loss per diluted share		1,573		1,573
Stock Options
Earnings Per Share Basic [Line Items]
Shares excluded from the calculation of net loss per diluted share	1,193	629	1,193	629

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Anti-Dilutive Weighted Average Shares Excluded From Diluted Net Loss Per Share Diluted Shares Calculation (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Restricted stock awards and units	2,135	1,954	2,129	1,759
Restricted Stock Awards and Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Restricted stock awards and units	995	1,417	1,033	1,431
Outstanding Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Restricted stock awards and units	1,140	537	1,096	328